Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
All News
The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.
Cryotherapy is a non-FDA approved treatment that has been promoted to treat post-athletic injury, osteoarthritis,rheumatoid arthritis, fibromyalgia, alzheimers, migraines, asthma, multiple sclerosis, etc. Cryotherapy may be as simple as ice packs on a localized portion of the body, such as the lower back, or may involve whole body cryotherapy.
Since the introduction of TNF inhibitors nearly 20 years ago, concerns over a potential associated cancer risk have abounded. The recent ACR RA treatment guidelines have addressed this recently, stating that patients with any solid tumor cancer or risk thereof should be treated as if they ha
Prevalent patients with ankylosing spondylitis (AS) face a 30–50% increased risk of acute coronary, cerebrovascular, and thromboembolic events compared with the general population.
Dr. Cush reviews highlights published this week at RheumNow.com.
A substantial, but unclear, percentage of patients presenting with new onset inflammatory polyarthritis (IP) will spontaneously remit, while others may persist and develop rheumatoid arthritis (RA).
The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
The impact of systemic glucocorticoid exposure on fracture risk among new-onset rheumatoid arthritis (RA) was studied using administrative claims data detailing the treatments and outcomes of 42,127 newly diagnosed RA patients (between 2005-2012).
Dr. Jack Cush reviews the news, reports and highlights from EULAR and the last 2 weeks from RheumNow.com.
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
Secukinumab (Cosentyx) has recently been approved for use in ankylosing spondylitis and psoriatic arthritis; the latter largely based on the FUTURE 2 and the just reported FUTURE 1 clinical trial. FUTURE 1 demonstrates the efficacy and safety of secukinumab, with inital weekly intravenous loading, given monthly as a subcutaneous injection.
Research presented at the annual British Society for Rheumatology conference revealed that rheumatoid arthritis patients who drink moderately while taking methotrexate appear to be at no greater risk for liver damage than nondrinkers.
Watch Dr. Cush discuss the highlights from this week on RheumNow.com.
Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.
Early referral and diagnosis remains a challenge for many who care for patients with musculoskeletal complaints. This is especially so in those with chronic low back pain (LBP) and the minority who will have ankylosing spondylitis or axial spondyloarthritis.
